Skip to Main Content

Andrew H. Ko


Colorectal and gastrointestinal cancer specialist
East Coast transplant and lover of piano, singing and sports

Dr. Andrew H. Ko is a specialist in colorectal and gastrointestinal cancers, with a particular focus on pancreatic cancer. He is interested in the development of new treatment strategies, including molecularly targeted therapies, which block cancer cell activity by interfering with specific molecules.

Ko earned an undergraduate degree in applied mathematics and biology at Brown University. He earned his medical degree at the Johns Hopkins School of Medicine. After a residency at Beth Israel Deaconess Medical Center, he completed a fellowship in medical oncology at Stanford University. He joined UCSF in 2001.

  • Education

    Johns Hopkins University, 1995

  • Residencies

    Beth Israel Hospital-Boston, MA, Internal Medicine, 1998

  • Fellowships

    Stanford University Medical Center, 2001

  • Board Certifications

    Medical Oncology, American Board of Internal Medicine

  • Academic Title


I am honored to partner with patients as I provide compassionate, thoughtful and cutting-edge care during a challenging time in their lives.

Where I see patients (2)

    My reviews


    Overall Experience
    203 Ratings
    Explained things in a way that was easy to understand
    202 Ratings
    Did the doctor pay attention to your concerns
    203 Ratings
    Gave easy to understand instructions about taking care of health problems or concerns
    202 Ratings
    Knew the important information about your medical history
    202 Ratings
    The provider showed respect for what you had to say
    202 Ratings
    The provider spent enough time with me
    201 Ratings
    Decorative Caduceus

    A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

    Overall survival (OS) is defined from the time of initiation of treatment until death due to any cause. Subjects still alive at the time of an analysis will be considered censored at their date of last contact.


    Decorative Caduceus

    Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastroint...

    To assess the efficacy of ulixertinib and hydroxychloroquine in patients with advanced, RAS, non-V600 BRAF, ERK, or MEK mutated gastrointestinal malignancies


    Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF are covered by every insurance plan.